Pain Management in Erythromelalgia: A Systematic Review and Graded Appraisal Across Etiological Subtypes.
Camille Racca, Sarah Berthelot, Julia Franken et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review evaluated pain management strategies for erythromelalgia across various etiological subtypes, analyzing 25 studies involving 591 individuals. Moderate-certainty evidence supports the use of aspirin for myeloproliferative neoplasm-associated erythromelalgia, while low-certainty evidence suggests potential benefits from mexiletine and carbamazepine in primary erythromelalgia. The review highlights the need for further research to validate these findings.
Key findings
- Moderate-certainty evidence supports aspirin for myeloproliferative neoplasm-associated erythromelalgia.
- Low-certainty evidence suggests mexiletine and carbamazepine may benefit primary erythromelalgia.
- Prostaglandin analogues and corticosteroids show low-certainty evidence for specific contexts.
- Evidence for selective Na+1.7 inhibitors and most other interventions is of very low certainty.
Why it matters
Understanding effective pain management strategies for erythromelalgia is crucial due to its complex pathophysiology and variable treatment responses. This review provides insights that may guide clinicians in selecting appropriate therapies based on aetiological subtypes.